Doxylamine succinate

{{DrugProjectFormSinglePage |authorTag=Kiran Singh, M.D. [1] |genericName=doxylamine succinate |aOrAn=an |drugClass=antihistamine |indicationType=treatment |indication=allergic rhinitis, common cold, insomnia |adverseReactions=somnolence |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

• Content

|fdaLIADAdult===Indications==

• Nighttime sleep-aid

Dosage

• Take one tablet 30 minutes before going to bed; take once daily or as directed by a doctor

|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Doxylamine Succinate in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Doxylamine Succinate in adult patients. |fdaLIADPed===Indications==

• Nighttime sleep-aid

Dosing

• Children 12 years of age and over: take one tablet 30 minutes before going to bed; take once daily or as directed by a doctor

• Children under 12 years of age: do not use

|offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Doxylamine Succinate in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Doxylamine Succinate in pediatric patients. |warnings=Do not give

• To children under 12 years of age

Ask a doctor before use if you have

• A breathing problem such as asthma, emphysema or chronic bronchitis
• Glaucoma
• Trouble urinating due to an enlarged prostate gland

Ask a doctor or pharmacist before use if you are

• Taking any other drugs

When using this product

• Avoid alcoholic beverages
• Take only at bedtime

Stop use and ask a doctor if

• Sleeplessness persists continuously for more than two weeks. Insomnia may be a symptom of serious underlying medical illness.

If pregnant or breast-feeding,

• Ask a health professional before use

Keep out of reach of children

• In case of overdose, get medical help or contact a Poison Control Center right away.

|clinicalTrials=There is limited information regarding Clinical Trial Experience of Doxylamine Succinate in the drug label. |postmarketing=There is limited information regarding Postmarketing Experience of Doxylamine Succinate in the drug label. |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Doxylamine Succinate in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Doxylamine Succinate during labor and delivery. |useInNursing=There is no FDA guidance on the use of Doxylamine Succinate with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Doxylamine Succinate with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Doxylamine Succinate with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Doxylamine Succinate with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Doxylamine Succinate with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Doxylamine Succinate in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Doxylamine Succinate in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Doxylamine Succinate in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Doxylamine Succinate in patients who are immunocompromised. |administration=* Oral |monitoring=There is limited information regarding Monitoring of Doxylamine Succinate in the drug label. |IVCompat=There is limited information regarding IV Compatibility of Doxylamine Succinate in the drug label. |overdose=There is limited information regarding Chronic Overdose of Doxylamine Succinate in the drug label. |drugBox=